SynthesisFrontiers in immunology2026
Efficacy and safety of immunotherapy combined with chemoradiotherapy in limited-stage small cell lung cancer: a systematic evaluation and meta-analysis of randomized controlled trials.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Concurrent chemoradiotherapy (cCRT) remains the standard treatment for patients diagnosed with limited-stage small-cell lung cancer (LS-SCLC); however, recurrence rates remain high and prognosis remains poor. This study collected data regarding patient-reported outcomes and adverse events (AEs) to evaluate the effects of chemoradiotherapy combined with immunotherapy in patients with LS-SCLC. Methods: A systematic literature search of 7 electronic databases was conducted for randomized, placebo-controlled trials enrolling patients diagnosed with LS-SCLC who received chemoradiotherapy combined with immunotherapy. Trials with unstratified LS-SCLC samples were excluded. A subsequent meta-analysis was performed. This study was registered with the International Prospective Register of Systematic Reviews (PROSPERO) under accession number CRD42024607159. Results: Nine trials comprising 1,853 patients were included. CCRT combined with immunotherapy exhibited a significant favorable trend in survival outcomes, with hazard ratios (HRs) for median progression-free survival (mPFS) and median overall survival (mOS) of Conclusion: CCRT combined with immunotherapy improved survival in patients with LS-SCLC, especially in the consolidation immunotherapy group. The treatment regimen was generally well tolerated, with an acceptable incidence of treatment-related adverse events (TRAEs). Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42024607159.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.